Export 13 results:
Author Title [ Type(Desc)] Year
Filters: Author is Remington, Gary  [Clear All Filters]
Journal Article
Caravaggio F, Fervaha G, Iwata Y, Plitman E, Chung JKu, Nakajima S, Mar W, Gerretsen P, Kim J, Chakravarty MM et al..  2018.  Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia.. Int J Geriatr Psychiatry. 33(3):523-530.
Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, DeRosse P, Remington G, Mulsant BH, Linke J et al..  2015.  Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis.. JAMA Psychiatry. 72(5):446-55.
Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JKu, Caravaggio F, Iwata Y, Remington G et al..  2014.  Glutamate-mediated excitotoxicity in schizophrenia: a review.. Eur Neuropsychopharmacol. 24(10):1591-605.
Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M et al..  2020.  Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity.. J Psychiatr Res. 124:151-158.
Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A.  2015.  Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance.. Hum Brain Mapp. 36(1):213-25.
Caravaggio F, Gerretsen P, Mar W, Chung JKu, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM et al..  2017.  Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.. Psychoneuroendocrinology. 81:80-87.
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JKu, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G et al..  2017.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.. Schizophr Bull.
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M et al..  2019.  Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.. Neuropsychopharmacology.
Kim J, Plitman E, Iwata Y, Nakajima S, Mar W, Patel R, Chavez S, Chung JKu, Caravaggio F, Chakravarty MM et al..  2019.  Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders.. Prog Neuropsychopharmacol Biol Psychiatry. :109839.
Behdinan T, Foussias G, Wheeler AL, Stefanik L, Felsky D, Remington G, Rajji TK, Chakravarty MM, Voineskos AN.  2015.  Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up.. Schizophr Res. 169(1-3):69-75.
Caravaggio F, Chung JKu, Plitman E, Boileau I, Gerretsen P, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G et al..  2017.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [(11) C]-raclopride and [(11) C]-(+)-PHNO PET.. Hum Brain Mapp. 38(11):5519-5534.
Plitman E, Chavez S, Nakajima S, Iwata Y, Chung JKu, Caravaggio F, Kim J, Alshehri Y, Chakravarty MM, De Luca V et al..  2018.  Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.. Psychiatry Res Neuroimaging. 273:16-24.
Caravaggio F, Plitman E, Chung JKu, Gerretsen P, Kim J, Iwata Y, Chakravarty MM, Remington G, Graff-Guerrero A.  2017.  Trait impulsiveness is related to smaller post-commissural putamen volumes in males but not females.. Eur J Neurosci. 46(7):2253-2264.